beta

CGIX

Cancer Genetics, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.

Market Cap: 6.38 Million

Primary Exchange: NASDAQ

Website: http://www.cancergenetics.com

Shares Outstanding: 2.1 Million

Float: 1.85 Million

Dividend: (%)

Beta: 0.74144912290849

Sector: Health Technology

Industry: Medical Specialties

Ethical Flags

Longest drawdown: 1743 trading days

From: 2013-09-27 To: 2020-05-22

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud